Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
- Sponsor
- University of Magdeburg
- Study ID
- NCT00385125
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Lymphoma, High-Grade
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Bendamustine — DRUG
- Rituximab — DRUG
Study Details
Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment, who received or did not qualify for autologous stem cell transplantation.
Key Dates
- Start date
- Aug 31, 2004
- Status verified
- Oct 2006
- Completion
- Aug 31, 2010
Study Design
- Enrollment
- 30 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
response rate
Central Contacts
- Martin Mohren, PD0049 231 6713266